The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Major depressive disorder (MDD) is common and often has sub-optimal response to treatment. Difficult-to-treat depression (DTD) is a new concept that describes ‘depression that continues to cause significant burden despite usual treatment efforts’. Aims: To identify patients with likely DTD in UK secondary care and examine demographic, disease and treatment data as compared with ‘non-DTD’ MDD patients. Methods: Anonymised electronic health records (EHRs) of five specialist mental health National Health Service (NHS) Trusts in the United Kingdom were analysed using a natural language processing model. Data on disease characteristics, comorbidities and treatment histories were extracted from structured fields and using natural language algorithms from unstructured fields. Patients with MDD aged ⩾18 years were included in the analysis; those with presumed DTD were identified on the basis of MDD history (duration and recurrence) and number of treatments prescribed. Results: In a sample of 28,184 patients with MDD, 19% met criteria for DTD. Compared to the non-DTD group, patients with DTD were more likely to have severe depression, suicidal ideation, and comorbid psychiatric and/or physical illness, as well as higher rates of hospitalisation. They were also more likely to be in receipt of unemployment and sickness/disability benefits. More intensive treatment strategies were used in the DTD group, including higher rates of combination therapy, augmentation, psychotherapy and electroconvulsive therapy. Conclusion: This study demonstrates the feasibility of identifying patients with probable DTD from EHRs and highlights the increased burden associated with MDD in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The related, but separate, notion of DTD seems more aligned with the realities of the clinical ecosystem, and with patient experi ence of depression and sequential non- re sponse to treatments 94,286 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [286]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIMIC-III, a freely accessible critical care database
Johnson, A. E. W., Pollard, T. J., Shen, L., Lehman, L.-W. H., Feng, M., Ghassemi, M., Moody, B., Szolovits, P., Anthony Celi, L., & Mark, R. G. (2016) · Scientific Data · doi:10.1038/sdata.2016.35 · Cited by 8,141 · cited 1×
“The Med7 NLP model was originally trained on general physical health data (Johnson et al., 2016), being then fine-tuned on the UK-CRIS EHR data to learn domain knowledge of mental health records (Kormilitzin et al., 2021).”
MethodScoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,381
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“For those who do not respond, an alternative treatment can be tried, but a significant proportion of patients do not achieve remission despite serial treatments (Rush et al., 2006).”
BackgroundMalhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“In the largest clinical trial ever conducted of what would be consistent with first-line UK treatment of MDD, the selective serotonin reuptake inhibitor (SSRI) citalopram led to around 30% of patients being relatively free of symptoms, that is, in remission (Trivedi et al., 2006).”
BackgroundThe Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779 · cited 1×
“The presence of comorbidity is a major driver of the economic burden of MDD, with 62% of total health care costs being due to comorbid conditions rather than MDD itself (Greenberg et al., 2015).”
BackgroundMultimorbidity and depression: A systematic review and meta-analysis
Read, J. R., Sharpe, L., Modini, M., & Dear, B. F. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.009 · Cited by 869 · cited 1×
“Conversely, depression is twice as likely in those individuals with multimorbidity than those with only one comorbidity, and three times as likely than those with no comorbidity (Read et al., 2017).”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 6×
“Olanzapine was the next most common augmentation agent, despite only being a second-line recommendation in most guidelines (Cleare et al., 2015; Taylor et al., 2020).”
BackgroundMethodResultInfluentialfor the European Depression in Diabetes (EDID) Research Consortium, Nouwen, A., Winkley, K., Twisk, J., Lloyd, C. E., Peyrot, M., Ismail, K., & Pouwer, F. (2010) · Diabetologia · doi:10.1007/s00125-010-1874-x · Cited by 756 · cited 1×
“It is also frequently comorbid with a range of physical disorders such as type 2 diabetes, asthma, gastrointestinal and musculoskeletal conditions (Gagnon and Patten, 2002; Nouwen et al., 2010).”
Paying the price: the cost of mental health care in England to 2026
McCrone, P., Dhanasiri, S., Patel, A. K., Knapp, M. R. J., & Lawton-Smith, S. H. (2008) · Research Portal (King's College London) · Cited by 591
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447 · cited 1×
“Most commonly, TRD is defined as a failure to respond to adequate trials of two different treatments (Brown et al., 2019; Gaynes et al., 2020) but there is lack of consensus regarding the required length of trial, dose of drug for depression and outcome measures to assess response for those treatment trials.”
BackgroundCai, W., Mueller, C., Li, Y.-J., Shen, W.-D., & Stewart, R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.013 · Cited by 359 · cited 1×
“There are strong suggestions of a particular association with cardiovascular dysfunction (Cai et al., 2019; Feng et al., 2019).”
BackgroundJohnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321 · cited 1×
“In addition, more treatment failures, and thus a greater degree of TRD, are associated with higher health care costs (Johnston et al., 2019; Russell et al., 2004).”
BackgroundMcAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278 · cited 5×
“‘Difficult-to-treat depression (DTD)’ is a new concept and a proposed definition is ‘depression that continues to cause significant burden despite usual treatment efforts’ (McAllister-Williams et al., 2020).”
BackgroundInfluentialBerman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 1×
“Aripiprazole was used at a lower rate and may be underused considering it is an effective augmentation strategy with an excellent metabolic side-effect profile and dopaminergic effects (Berman et al., 2009).”
BackgroundComorbid psychiatric disorders in depressed outpatients: Demographic and clinical features
Rush, A. J., Zimmerman, M., Wisniewski, S. R., Fava, M., Hollon, S. D., Warden, D., Biggs, M. M., Shores-Wilson, K., Shelton, R. C., Luther, J. F., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.03.005 · Cited by 254 · cited 1×
“MDD is highly comorbid with many other mental health conditions including anxiety, post-traumatic stress disorder (PTSD), eating disorders and substance misuse (Rush et al., 2005).”
BackgroundSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214 · cited 4×
“The same guidelines recommend that failed courses of psychotherapy should not be considered as one of the previous treatments required to meet criteria for TRD, but with some disagreement between experts (Sforzini et al., 2021).”
BackgroundMethodInfluentialMed7: A transferable clinical natural language processing model for electronic health records
Kormilitzin, A., Vaci, N., Liu, Q., & Nevado‐Holgado, A. J. (2021) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2021.102086 · Cited by 185
Brown, S., Rittenbach, K., Cheung, S., McKean, G., MacMaster, F. P., & Clement, F. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719828965 · Cited by 151 · cited 6×
“Even the ‘classic’ criteria of failure to respond to two drugs for depression (‘antidepressants’), the most common element in TRD definitions, was present in just 50.3% of 150 trials systematically reviewed (Brown et al., 2019).”
BackgroundInfluentialDifficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
The Cost Consequences of Treatment-Resistant Depression
Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., Finkelstein, S., Berndt, E., & Rush, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0309 · Cited by 117 · cited 1×
“In addition, more treatment failures, and thus a greater degree of TRD, are associated with higher health care costs (Johnston et al., 2019; Russell et al., 2004).”
BackgroundPrevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis
Feng, L., Li, L., Liu, W., Yang, J., Wang, Q., Shi, L., & Luo, M. (2019) · Medicine · doi:10.1097/md.0000000000014596 · Cited by 113 · cited 1×
“There are strong suggestions of a particular association with cardiovascular dysfunction (Cai et al., 2019; Feng et al., 2019).”
BackgroundMortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors, J., Andersson, T. M.-L., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hägg, D., Wingård, L., & Bodén, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.030 · Cited by 94 · cited 2×
“, 2019), Sweden (Reutfors et al., 2018) and Hungary (Dome et al.”
BackgroundClinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89 · cited 1×
“This basic understanding is a fundamental initial step for the research, design and commission of clinical services for patients with DTD (Martin-Cook et al., 2021; Rush et al., 2022).”
BackgroundSelf-citationLi, G., Fife, D., Wang, G., Sheehan, J. J., Bodén, R., Brandt, L., Brenner, P., Reutfors, J., & DiBernardo, A. (2019) · Annals of General Psychiatry · doi:10.1186/s12991-019-0248-0 · Cited by 83 · cited 2×
“Data from North America (Li et al., 2019), Sweden (Reutfors et al.”
BackgroundPharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76 · cited 1×
“Olanzapine was the next most common augmentation agent, despite only being a second-line recommendation in most guidelines (Cleare et al., 2015; Taylor et al., 2020).”
BackgroundObstacles to effective treatment of depression: a general practice perspective
Telford, R. (2002) · Family Practice · doi:10.1093/fampra/19.1.45 · Cited by 69 · cited 1×
“Data from UK primary care suggest that accessing specialist mental health services can be challenging (Telford et al., 2002) and only a small proportion of patients presenting with TRD in primary care are referred to secondary care (Wiles et al.”
BackgroundMajor Depression and its Association with Long-Term Medical Conditions
Gagnon, L. M., & Pat ten, S. B. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700204 · Cited by 66 · cited 1×
“It is also frequently comorbid with a range of physical disorders such as type 2 diabetes, asthma, gastrointestinal and musculoskeletal conditions (Gagnon and Patten, 2002; Nouwen et al., 2010).”
BackgroundNatural language processing for structuring clinical text data on depression using UK-CRIS
Vaci, N., Liu, Q., Kormilitzin, A., De Crescenzo, F., Kurtulmus, A., Harvey, J., O'Dell, B., Innocent, S., Tomlinson, A., Cipriani, A., et al. (2020) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300134 · Cited by 63 · cited 4×
“To identify patients, a retrospective audit of deidentified electronic health records (EHRs) was performed using the UK-Clinical Records Interactive Search (UK-CRIS) system (Vaci et al., 2020).”
BackgroundMethodResultInfluentialManagement of treatment-resistant depression in primary care: a mixed-methods study
Wiles, N., Taylor, A., Turner, N., Barnes, M., Campbell, J., Lewis, G., Morrison, J., Peters, T. J., Thomas, L., Turner, K., et al. (2018) · British Journal of General Practice · doi:10.3399/bjgp18x699053 · Cited by 45
Multiple-therapy-resistant major depressive disorder: a clinically important concept
McAllister-Williams, R. H., Christmas, D. M. B., Cleare, A. J., Currie, A., Gledhill, J., Insole, L., Malizia, A. L., McGeever, M., Morriss, R., Robinson, L. J., et al. (2018) · British Journal of Psychiatry · doi:10.1192/bjp.2017.33 · Cited by 40 · cited 2×
“TRD definitions also rarely take into account non-response to psychotherapy or neurostimulatory treatments (Brown et al., 2019; McAllister-Williams et al., 2018).”
BackgroundMethodDöme, P., Kunovszki, P., Takács, P., Fehér, L., Balázs, T., Dede, K., Mulhern-Haughey, S., Barbreau, S., & Rihmer, Z. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245510 · Cited by 40 · cited 2×
“, 2018) and Hungary (Dome et al., 2021) have shown that patients with TRD have significantly higher all-cause mortality than other depressed patients.”
BackgroundGoodday, S. M., Kormilitzin, A., Vaci, N., Liu, Q., Cipriani, A., Smith, T., & Nevado-Holgado, A. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2020.103429 · Cited by 34 · cited 3×
“, 2019), and a high rate of missing data has been observed for social and behavioural parameters in EHRs (Goodday et al., 2020).”
BackgroundResultReconceptualising treatment‐resistant depression as difficult‐to‐treat depression
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30516-2 · Cited by 30
Martin-Cook, K., Palmer, L., Thornton, L., Rush, A. J., Tamminga, C. A., & Ibrahim, H. M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s308615 · Cited by 25 · cited 1×
“This basic understanding is a fundamental initial step for the research, design and commission of clinical services for patients with DTD (Martin-Cook et al., 2021; Rush et al., 2022).”
BackgroundMcAllister-Williams, H., Bulmer, S., Newton, K. S., Heath, K., Cousins, D. A., & Currie, A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.020 · Cited by 21 · cited 2×
“We do not have data on numbers of patients who were referred to tertiary care for more specialist treatment; for example, alternative neurostimulatory options such as vagus nerve stimulation (VNS) that may have a place in some patients with DTD (McAllister-Williams et al., 2021b).”
BackgroundPearsall, R., Shaw, R. J., McLean, G., Connolly, M., Hughes, K. A., Boyle, J. G., Park, J., Smıth, D. J., & Mackay, D. (2019) · BJPsych Open · doi:10.1192/bjo.2019.76 · Cited by 10 · cited 2×
“For example, rates of physical health screening and diagnosis of physical illnesses is known to be sub-optimal in patients with mental illness (Pearsall et al., 2019), and a high rate of missing data has been observed for social and behavioural parameters in EHRs (Goodday et al., 2020).”
Background
Research works printed but not linked: 2
- NICE (2009) Depression in Adults: Treatment and Management – Clinical Guideline [CG90]. London: NICE.
- WHO (2017) Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Artificial intelligence-based suicide prevention and prediction: A systematic review (2019–2023)
Atmakuru, A., Shahini, A., Chakraborty, S., Seoni, S., Salvi, M., Hafeez‐Baig, A., Rashid, S., Tan, R., Barua, P. D., Molinari, F., et al. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102673 · Cited by 49
Pappa, S., Shah, M., Young, S., Anwar, T., & Ming, T. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.022 · Cited by 21
Difficult-To-Treat Depression. Scoping Review.
Paganin, W., Signorini, S. G., & Sciarretta, A. (2023) · PubMed Central · doi:10.36131/cnfioritieditore20230302 · Cited by 28
“…NL 16 Riveros et al., 2022 Review Article Antioxidants Switzerland 17 Moeller et al., 2022 Review Article Nordic Journal of Psychiatry UK 18 Sforzini et al., 2022 Review Article Molecular Psychiatry USA 19 Costa et al., 2022 Original Article Journal of Psychopharmacology UK 20 Rosana Silva.”
BackgroundGill, K., Hett, D., Carlish, M., Amos, R., Khatibi, A., Morales‐Muñoz, I., & Marwaha, S. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.275 · Cited by 17
“10,11 Most research has relied on large cohort studies using electronic health records (EHRs), with few studies having used mixed-methods approaches that include patient and clinician perspectives.”
Metadata
- Authors
- Costa, T., Menzat, B., Engelthaler, T., Fell, B., Franarin, T., Roque, G., Wei, Y., Zhang, X., & McAllister-Williams, R. H.
- Affiliations
- Cumbria Northumberland Tyne and Wear NHS Foundation Trust (GB)
- Akrivia Health, Oxford Centre for Innovation, Oxford, UK
- Northern Centre for Mood Disorders, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-05
- Volume
- 36
- Issue
- 5
- Pages
- 545-556
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC9112623
- OpenAlex
- W4229030116
- Cited by
- 22
- References
- 38
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 9 · 2023: 2 · 2022: 1
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- LivaNova (Commissioned and funded the study and analysis)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- difficult-to-treat depression, major depressive disorder, treatment burden, secondary care, comorbidities, suicidal ideation, hospitalization, treatment history, augmentation therapy, electroconvulsive therapy, psychotherapy, natural language processing, electronic health records
- MeSH terms
- Aged, Depression, Major Depressive Disorder, Humans, Psychotherapy, State Medicine, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
